SI2731973T1 - Bakterijski gostiteljski sev, ki izraža rekombinantni DSBC - Google Patents
Bakterijski gostiteljski sev, ki izraža rekombinantni DSBC Download PDFInfo
- Publication number
- SI2731973T1 SI2731973T1 SI201231206T SI201231206T SI2731973T1 SI 2731973 T1 SI2731973 T1 SI 2731973T1 SI 201231206 T SI201231206 T SI 201231206T SI 201231206 T SI201231206 T SI 201231206T SI 2731973 T1 SI2731973 T1 SI 2731973T1
- Authority
- SI
- Slovenia
- Prior art keywords
- seq
- bacterial cell
- antibody
- gram
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Claims (15)
- Bakterijski gostiteljski sev, ki izraža rekombinantni DsbC Patentni zahtevki1. Rekombinantna gramnegativna bakterijska celica, ki obsega: a) ekspresijski vektor, ki obsega rekombinantni polinukleotid, ki kodira DsbC; in b) enega ali več polinukleotidov, ki kodirajo protitelo ali njegov antigen-vezavni fragment, ki se specifično veže na CD154; c) mutiran gen Tsp, ki kodira beljakovino Tsp, ki ima 50 % ali manj proteazne aktivnosti nemutirane beljakovine Tsp divjega tipa, kot je prikazana na SEQ ID NO: 26 in; d) mutiran gen spr, ki kodira beljakovino spr, katere zaporedje divjega tipa je prikazano na SEQ ID NO: 24, ki obsega mutacijo, ki zadeva aminokislino C94; in pri čemer je gramnegativna bakterijska celica izbrana iz sevov E. coli K12 in VV3110 in pri čemer je bakterijska celica izogena omenjenim sevom, razen rekombinantnega polinukleotida, ki kodira DsbC, pri čemer en ali več polinukleotidov kodira protitelo ali njegov antigen-vezavni fragment, ki se specifično veže na CD154 in mutirani gen Tsp in mutirani gen spr;
- 2. Gramnegativna bakterijska celica po zahtevku 1, pri čemer DsbC obsega histidinski označevalec na N-koncu ali C-koncu.
- 3. Gramnegativna bakterijska celica po zahtevku 1 ali 2, pri čemer ekspresijski vektor obsega polinukleotid, ki ima zaporedje, podano v SEQ ID NO:45 ali SEQ ID NO:51.
- 4. Gramnegativna bakterijska celica po katerem koli od zahtevkov od 1 do 3, pri čemer protitelo ali njegov antigen-vezavni fragment obsega variabilno domeno težke verige, ki obsega tri CDR-je, ki imajo zaporedje podano v SEQ ID NO: 1 za CDRH1, SEQ ID NO: 2, za CDRH2 in SEQ ID NO: 3 za CDRH3 in variabilno domeno lahke verige, ki obsega tri CDR-je, ki imajo zaporedje podano v SEQ ID NO: 4 za CDRL1, SEQ ID NO: 5 za CDRL2 in SEQ ID NO: 6 za CDRL3.
- 5. Gramnegativna bakterijska celica po zahtevku 4, pri čemer en ali več polinukleotidov kodira protitelo, ki obsega zaporedje variabilne regije lahke verige, ki je podano v SEQ ID NO:8, in variabilno regijo težke verige, ki je podana v SEQ ID NO:10.
- 6. Gramnegativna bakterijska celica po katerem koli od zahtevkov od 1 do 5, pri čemer je protitelo fragment Fab ali Fab‘.
- 7. Gramnegativna bakterijska celica po zahtevku 6, pri čemer fragment Fab ali Fab‘ obsega lahko verigo, ki ima zaporedje, podano v SEQ ID NO: 12 in težko verigo, ki ima zaporedje, podano v SEQ ID NO:14 ali 16.
- 8. Gramnegativna bakterijska celica po katerem koli od zahtevkov od 1 do 7, pri čemer gramnegativna bakterijska celica obsega prvi ekspresijski vektor, ki obsega rekombinantni polinukleotid, ki kodira DsbC, in drugi ekspresijski vektor, ki obsega enega ali več polinukleotidov, ki kodirajo protitelo ali njegov antigen-vezavni fragment, ki se specifično veže na CD154.
- 9. Gramnegativna bakterijska celica po katerem koli od zahtevkov od 1 do 7, pri čemer ekspresijski vektor, ki obsega rekombinantni polinukleotid, ki kodira DsbC, dodatno obsega enega ali več polinukleotidov, ki kodirajo protitelo ali njegov antigen-vezavni fragment, ki se specifično veže na CD154.
- 10. Gramnegativna bakterijska celica po katerem koli predhodnem zahtevku, pri čemer mutacija v genu spr, ki kodira beljakovino spr, privede do spremembe aminokisline cistein v alanin na položaju 94 (C94A).
- 11. Gramnegativna bakterijska celica po katerem koli od zahtevkov od 1 do 10, ki obsega ekspresijski vektor, ki obsega rekombinantni polinukleotid, ki kodira DsbC in dicistronsko sporočilo za tvorbo protitelesa ali njegovega antigen-vezavnega fragmenta, ki se specifično veže na CD154, pri čemer zgornji cistron vsebuje DNA, ki kodira lahko verigo protitelesa, in spodnji cistron vsebuje DNA, ki kodira ustrezno težko verigo, označena s tem, da dicistronsko sporočilo obsega zaporedje, izbrano izmed IGS1 (SEQ ID NO: 33), IGS2 (SEQ ID NO: 34), IGS3 (SEQ ID NO: 35) in IGS4 (SEQ ID NO: 36).
- 12. Postopek za tvorbo protitelesa ali njegovega antigen-vezavnega fragmenta, ki se specifično veže na CD154, pri čemer postopek obsega: a) gojenje rekombinantne gramnegativne bakterijske celice, kot je definirana v katerem koli od zahtevkov od 1 do 11, v gojišču v pogojih, ki so učinkoviti za izražanje protitelesa ali njegovega antigen-vezavnega fragmenta, ki se specifično veže na CD154, in rekombinantnega polinukleotida, ki kodira DsbC; in b) pridobivanje protitelesa ali njegovega antigen-vezavnega fragmenta, ki se specifično veže na CD154, iz periplazme rekombinantne gramnegativne bakterijske celice in/ali gojišča.
- 13. Postopek po zahtevku 12, pri čemer postopek dalje obsega korak pritrjanja efektorske molekule na aminokislino pri ali proti C-koncu težke verige in/ali lahke verige protitelesa.
- 14. Postopek po zahtevku 13, pri čemer efektorska molekula obsega poli(etilenglikol) ali metoksipoli(etilenglikol).
- 15. Postopek po zahtevku 14, pri čemer postopek obsega pritrjanje lizil-maleimidne skupine na enem od cisteinskih ostankov pri C-koncu težke verige, pri čemer ima vsaka amino skupina lizilnega ostanka nase kovalentno vezan metoksipoli(etilenglikolni) ostanek, ki ima molekulsko maso okoli 20.000 Da.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11173880 | 2011-07-13 | ||
| PCT/EP2012/002945 WO2013007388A1 (en) | 2011-07-13 | 2012-07-13 | Bacterial host strain expressing recombinant dsbc |
| EP12737492.4A EP2731973B1 (en) | 2011-07-13 | 2012-07-13 | Bacterial host strain expressing recombinant dsbc |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2731973T1 true SI2731973T1 (sl) | 2018-04-30 |
Family
ID=46545736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201231206T SI2731973T1 (sl) | 2011-07-13 | 2012-07-13 | Bakterijski gostiteljski sev, ki izraža rekombinantni DSBC |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9725516B2 (sl) |
| EP (2) | EP2731973B1 (sl) |
| JP (3) | JP6431370B2 (sl) |
| KR (1) | KR102023786B1 (sl) |
| CN (1) | CN103649124B (sl) |
| AU (1) | AU2012283388B2 (sl) |
| BR (1) | BR112013032871B1 (sl) |
| CA (1) | CA2841824C (sl) |
| CY (1) | CY1119985T1 (sl) |
| DK (1) | DK2731973T3 (sl) |
| EA (1) | EA031449B1 (sl) |
| ES (1) | ES2659155T3 (sl) |
| HK (1) | HK1194393A1 (sl) |
| HR (1) | HRP20180226T1 (sl) |
| HU (1) | HUE035674T2 (sl) |
| IL (1) | IL229947B (sl) |
| IN (1) | IN2014DN00202A (sl) |
| LT (1) | LT2731973T (sl) |
| ME (1) | ME02957B (sl) |
| MX (1) | MX348738B (sl) |
| NO (1) | NO2731973T3 (sl) |
| PL (1) | PL2731973T3 (sl) |
| PT (1) | PT2731973T (sl) |
| RS (1) | RS56926B1 (sl) |
| SG (1) | SG10201807560XA (sl) |
| SI (1) | SI2731973T1 (sl) |
| WO (1) | WO2013007388A1 (sl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009010120A (es) * | 2007-03-22 | 2009-10-19 | Ucb Pharma Sa | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos. |
| HUE040306T2 (hu) | 2009-09-24 | 2019-03-28 | Ucb Biopharma Sprl | Baktériumtörzs rekombináns fehérje expresszálására, amely tartalmaz proteázhiányos, de chaperonaktivitását megtartott DEGP-t és génkiütött TSP és PTR gént |
| GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
| HUE035674T2 (en) * | 2011-07-13 | 2018-05-28 | Ucb Biopharma Sprl | Bacterial host strains expressing recombinant DSBC |
| GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
| GB201223276D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| EP4253548A3 (en) | 2014-12-22 | 2024-01-03 | UCB Biopharma SRL | Protein manufacture |
| KR101810778B1 (ko) * | 2015-06-23 | 2017-12-20 | 서울대학교산학협력단 | Cd154 결합 폴리펩타이드 및 그 용도 |
| AU2017212484C1 (en) | 2016-01-27 | 2020-11-05 | Medimmune, Llc | Methods for preparing antibodies with a defined glycosylation pattern |
| EP3877407A1 (en) * | 2018-11-05 | 2021-09-15 | F. Hoffmann-La Roche AG | Methods of producing two chain proteins in prokaryotic host cells |
| CN109371049A (zh) * | 2018-11-14 | 2019-02-22 | 天津大学 | 分子伴侣在促进单克隆抗体的形成和/或提高单克隆抗体的表达量中的应用 |
| EP3942079A1 (en) | 2019-03-18 | 2022-01-26 | Bio-Rad ABD Serotec GmbH | Protection of spytag-containing periplasmic fusion proteins from protease tsp and ompt degradation |
| WO2021023367A1 (de) * | 2019-08-05 | 2021-02-11 | Wacker Chemie Ag | Bakterienstamm zur freisetzung eines rekombinanten proteins in einem fermentationsverfahren |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
| US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| AU4118393A (en) | 1992-04-28 | 1993-11-29 | Regents Of The University Of Michigan, The | Human crabp-I and crabp-II |
| GB9215540D0 (en) | 1992-07-22 | 1992-09-02 | Celltech Ltd | Protein expression system |
| US5304472A (en) | 1992-11-20 | 1994-04-19 | Genentech, Inc. | Method of controlling polypeptide production in bacterial cells |
| US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
| AU2660397A (en) | 1996-04-05 | 1997-10-29 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
| JP2000083670A (ja) | 1998-09-09 | 2000-03-28 | Hsp Kenkyusho:Kk | ＤｓｂＡ／ＤｓｂＢ／ＤｓｂＣ／ＤｓｂＤ発現プラスミド |
| JP2003503074A (ja) | 1999-06-29 | 2003-01-28 | シガ・テクノロジーズ，インコーポレイテッド | Ｄｅｇｐプロテアーゼインヒビター類の分析方法 |
| GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| AU8867501A (en) | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| AU2001287040A1 (en) | 2000-09-01 | 2002-03-13 | Biogen, Inc. | Methods of designing and producing novel compounds having improved binding affinity for cd154 or other trimeric proteins |
| US7041479B2 (en) | 2000-09-06 | 2006-05-09 | The Board Of Trustess Of The Leland Stanford Junior University | Enhanced in vitro synthesis of active proteins containing disulfide bonds |
| ATE318890T1 (de) | 2000-12-14 | 2006-03-15 | Genentech Inc | Bakterielle wirtstämme |
| ATE405650T1 (de) | 2000-12-14 | 2008-09-15 | Genentech Inc | Produktion von ganzen antikörpern in prokaryontischen zellen |
| TWI327597B (en) | 2001-08-01 | 2010-07-21 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| NZ530852A (en) * | 2001-08-27 | 2006-11-30 | Genentech Inc | Methods and compositions for recombinantly producing functional antibodies or antibody fragments in prokaryotic and eukaryotic host cells |
| GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| JP2005535282A (ja) | 2001-11-16 | 2005-11-24 | アイデック ファーマシューティカルズ コーポレイション | 抗体のポリシストロニック発現 |
| GB0129105D0 (en) * | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
| JP2006512895A (ja) | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | リガンド |
| MXPA05004677A (es) | 2002-10-31 | 2005-11-17 | Genentech Inc | Metodos y composiciones para aumentar la produccion de anticuerpos. |
| JP4603894B2 (ja) | 2002-12-03 | 2010-12-22 | ユセベ ファルマ ソシエテ アノニム | 抗体産生細胞を同定するためのアッセイ |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| CA2528551A1 (en) | 2003-06-13 | 2005-01-13 | Biogen Idec Ma Inc. | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
| ATE414106T1 (de) | 2003-06-30 | 2008-11-15 | Domantis Ltd | Pegylierte single-domain-antikörper (dab) |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| CA2533593A1 (en) | 2003-07-26 | 2005-02-10 | Biogen Idec Ma Inc. | Altered antibodies having improved antigen-binding affinity |
| AU2005287406B2 (en) | 2004-07-26 | 2011-08-18 | Biogen Ma Inc. | Anti-CD154 antibodies |
| JP2008511337A (ja) * | 2004-09-02 | 2008-04-17 | ジェネンテック・インコーポレーテッド | ヘテロ多量体分子 |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| GB0425534D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Process for obtaining antibodies |
| GB0520169D0 (en) | 2005-10-04 | 2005-11-09 | Celltech R&D Ltd | Biological products |
| MX2009010120A (es) | 2007-03-22 | 2009-10-19 | Ucb Pharma Sa | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos. |
| EP2195341B1 (en) | 2007-09-26 | 2017-03-22 | UCB Biopharma SPRL | Dual specificity antibody fusions |
| US7662587B1 (en) | 2009-03-05 | 2010-02-16 | E. I. Du Pont De Nemours And Company | Gene knockout mutations that increase peptide production |
| HUE040306T2 (hu) | 2009-09-24 | 2019-03-28 | Ucb Biopharma Sprl | Baktériumtörzs rekombináns fehérje expresszálására, amely tartalmaz proteázhiányos, de chaperonaktivitását megtartott DEGP-t és génkiütött TSP és PTR gént |
| US8470552B2 (en) | 2009-10-12 | 2013-06-25 | Keck Graduate Institute | Strategy to reduce lactic acid production and control PH in animal cell culture |
| AU2010314981B2 (en) * | 2009-11-05 | 2015-07-02 | Genentech, Inc. | Methods and composition for secretion of heterologous polypeptides |
| GB201000591D0 (en) * | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000588D0 (en) * | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201001791D0 (en) | 2010-02-03 | 2010-03-24 | Ucb Pharma Sa | Process for obtaining antibodies |
| GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
| EP2546267A1 (en) | 2011-07-13 | 2013-01-16 | UCB Pharma S.A. | Bacterial host strain expressing recombinant DsbC |
| HUE035674T2 (en) | 2011-07-13 | 2018-05-28 | Ucb Biopharma Sprl | Bacterial host strains expressing recombinant DSBC |
| GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
-
2012
- 2012-07-13 HU HUE12737492A patent/HUE035674T2/en unknown
- 2012-07-13 ES ES12737492.4T patent/ES2659155T3/es active Active
- 2012-07-13 DK DK12737492.4T patent/DK2731973T3/da active
- 2012-07-13 IN IN202DEN2014 patent/IN2014DN00202A/en unknown
- 2012-07-13 NO NO12737492A patent/NO2731973T3/no unknown
- 2012-07-13 RS RS20180171A patent/RS56926B1/sr unknown
- 2012-07-13 EP EP12737492.4A patent/EP2731973B1/en active Active
- 2012-07-13 PL PL12737492T patent/PL2731973T3/pl unknown
- 2012-07-13 SI SI201231206T patent/SI2731973T1/sl unknown
- 2012-07-13 WO PCT/EP2012/002945 patent/WO2013007388A1/en active Application Filing
- 2012-07-13 AU AU2012283388A patent/AU2012283388B2/en active Active
- 2012-07-13 US US14/131,994 patent/US9725516B2/en active Active
- 2012-07-13 EP EP17196968.6A patent/EP3339325A1/en not_active Withdrawn
- 2012-07-13 SG SG10201807560XA patent/SG10201807560XA/en unknown
- 2012-07-13 ME MEP-2018-33A patent/ME02957B/me unknown
- 2012-07-13 CA CA2841824A patent/CA2841824C/en active Active
- 2012-07-13 LT LTEP12737492.4T patent/LT2731973T/lt unknown
- 2012-07-13 MX MX2014000302A patent/MX348738B/es active IP Right Grant
- 2012-07-13 EA EA201490274A patent/EA031449B1/ru not_active IP Right Cessation
- 2012-07-13 CN CN201280034512.9A patent/CN103649124B/zh active Active
- 2012-07-13 PT PT127374924T patent/PT2731973T/pt unknown
- 2012-07-13 KR KR1020137034718A patent/KR102023786B1/ko active IP Right Grant
- 2012-07-13 JP JP2014519454A patent/JP6431370B2/ja active Active
- 2012-07-13 BR BR112013032871-1A patent/BR112013032871B1/pt active IP Right Grant
-
2013
- 2013-12-17 IL IL22994713A patent/IL229947B/en active IP Right Grant
-
2014
- 2014-07-30 HK HK14107814.3A patent/HK1194393A1/zh unknown
-
2017
- 2017-08-03 US US15/667,649 patent/US9957328B2/en active Active
- 2017-10-31 JP JP2017209932A patent/JP2018019719A/ja active Pending
-
2018
- 2018-02-06 HR HRP20180226TT patent/HRP20180226T1/hr unknown
- 2018-02-15 CY CY20181100192T patent/CY1119985T1/el unknown
-
2019
- 2019-11-01 JP JP2019200029A patent/JP7062626B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2731973T1 (sl) | Bakterijski gostiteljski sev, ki izraža rekombinantni DSBC | |
| JP6392923B2 (ja) | Ｍｕｃ１＊抗体 | |
| JP7041516B2 (ja) | 共通軽鎖を有する二重特異性抗体又は抗体混合物 | |
| JP6034846B2 (ja) | タンパク質足場 | |
| JP2014521313A5 (sl) | ||
| TWI713942B (zh) | 與集落刺激因子１受體（ｃｓｆ１ｒ）結合之抗體類 | |
| JP7138046B2 (ja) | 二特異性抗体基幹 | |
| JP2018085988A5 (sl) | ||
| KR101796689B1 (ko) | 안정화된 면역글로불린가변도메인 선별방법 및 선별된 도메인의 응용 | |
| US20220220218A1 (en) | Anti-cd73 antibody, antigen-binding fragment thereof and application thereof | |
| JP2018502572A5 (sl) | ||
| HRP20160584T1 (hr) | Novo anti-dr5 antitijelo | |
| SI2703486T1 (sl) | Anti-b7-h3 protitelo | |
| CO6331299A2 (es) | Proteinas de union a antigeno de factor de crecimiento tipo factor de crecimiento epidermico de union a heparina | |
| HRP20171641T1 (hr) | Genetički polimorfizam kod makularne degeneracije vezane uz dob | |
| CN113234145A (zh) | 特异性结合新型冠状病毒的抗体 | |
| Silva et al. | Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses | |
| TW201632547A (zh) | 一種由噬菌體表現之單鏈變異片段抗體庫 | |
| JP2018512124A5 (sl) | ||
| RU2013105487A (ru) | Антитела против нейропилина и способы их применения | |
| JP2013539962A5 (sl) | ||
| AR103839A1 (es) | DÍMEROS scFv-Fc QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE b1 CON AFINIDAD, AVIDEZ Y ESPECIFICIDAD ELEVADAS | |
| WO2020057742A1 (en) | Vaccine and antibody against clostidioides difficile toxin | |
| Wezner-Ptasinska et al. | Selection of specific interactors from phage display library based on sea lamprey variable lymphocyte receptor sequences | |
| Sangpheak et al. | Investigation of interactions between binding residues and solubility of grafted humanized anti-VEGF IgG antibodies expressed as full-length format in the cytoplasm of a novel engineered E. coli SHuffle strain |